Add to Calendar
8/26/2020 8:00:00 AM8/27/2020 5:00:00 PM 2020 State of Possible Conference
Special thanks to our Platinum Sponsor Morgan Stanley
Registered attendees will receive an email with the subject line “Welcome to the State of Possible Conference 2020 - Event Access Link” from email@example.com.
The State of Possible Conference, MassBio's Annual Meeting, will now be hosted virtually on August 26-27, 2020. Featuring interactive networking and a groundbreaking viewer experience, this event will not be your average webinar.
We will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks®, inspiring and engaging content in the style of a TED Talk.
"It's the Woodstock of Life Sciences, with all-star performers playing their greatest hits all on one stage.” – 2019 State of Possible Conference attendee
If you haven’t attended our State of Possible Conference before, it is the premier east coast life sciences conference. We have some of the brightest names in biotech talking about the issues impacting our industry, covering topics from the realities of precision medicine to advancing new drug targets faster.
NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
Online Conference, Link will be sent in advance of the event.
Global Head of Evidence and Outcomes, Takeda
Kathleen Gondek, PhD, is currently the Global Head of Evidence and Outcomes at Takeda. She is responsible for developing and implementing global outcomes and epidemiology research strategies to establish the value proposition for Takeda products from early development through commercialization.
Prior to joining Takeda she was Vice President, US Medical Science Liaisons and Medical Affairs Operations at Bayer HealthCare pharmaceuticals and held a number of positions, of increasing responsibility, within the Health Economics and Outcomes Research (HEOR) function that span a 15-year career with the organization. Kathleen is a coauthor on 45 peer reviewed publications and over 100 presentations and has served on numerous external advisory committees including PCORI’s Rare Disease Advisory Panel.
Kathleen holds a Bachelor’s Degree in Pharmacy from the State University of New York at Buffalo and a Ph.D. in Pharmacy Practice and Administrative Science from the University of Maryland at Baltimore. Kathleen was a lecturer at Yale University in the School of Public Health. Kathleen currently serves on the board for the Arts and Business Council of Boston.